Nutriband Inc
NTRB
Company Profile
Business description
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Contact
121 South Orange Avenue
Suite 1500
OrlandoFL32801
USAT: +1 407 377-6695
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 January 2027
Employees
3
Stocks News & Analysis
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.60 | 20.80 | 0.23% |
| CAC 40 | 7,850.54 | 67.72 | 0.87% |
| DAX 40 | 25,401.63 | 219.98 | 0.87% |
| Dow JONES (US) | 52,402.52 | 187.36 | 0.36% |
| FTSE 100 | 10,755.45 | 65.09 | 0.61% |
| HKSE | 23,211.81 | 118.44 | 0.51% |
| NASDAQ | 26,014.69 | 59.35 | 0.23% |
| Nikkei 225 | 62,189.65 | 503.51 | -0.80% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,655.99 | 32.31 | 0.42% |
| S&P/ASX 200 | 8,809.90 | 14.70 | 0.17% |
| SSE Composite Index | 3,697.52 | 7.04 | 0.19% |